GDTC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GDTC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
CytoMed Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $0.85 Mil.
CytoMed Therapeutics's quarterly Total Liabilities declined from Dec. 2022 ($3.43 Mil) to Jun. 2023 ($0.55 Mil) but then increased from Jun. 2023 ($0.55 Mil) to Dec. 2023 ($0.85 Mil).
CytoMed Therapeutics's annual Total Liabilities increased from Dec. 2021 ($2.56 Mil) to Dec. 2022 ($3.43 Mil) but then declined from Dec. 2022 ($3.43 Mil) to Dec. 2023 ($0.85 Mil).
The historical data trend for CytoMed Therapeutics's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Total Liabilities | 2.51 | 2.56 | 3.43 | 0.85 |
CytoMed Therapeutics Semi-Annual Data | ||||||||
Dec20 | Jun21 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | ||
Total Liabilities | Get a 7-Day Free Trial | 2.56 | 2.60 | 3.43 | 0.55 | 0.85 |
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
CytoMed Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as
Total Liabilities | = | Total Current Liabilities | + | Total Noncurrent Liabilities | ||
= | Total Current Liabilities | + | (Long-Term Debt & Capital Lease Obligation | + | Other Long-Term Liabilities | |
= | 0.538 | + | (0.306 | + | 0.00099999999999995 | |
+ | NonCurrent Deferred Liabilities | + | PensionAndRetirementBenefit) | |||
+ | 0 | + | 0) | |||
= | 0.85 |
Total Liabilities | = | Total Assets (A: Dec. 2023 ) | - | Total Equity (A: Dec. 2023 ) |
= | 9.285 | - | 8.441 | |
= | 0.84 |
CytoMed Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as
Total Liabilities | = | Total Current Liabilities | + | Total Noncurrent Liabilities | ||
= | Total Current Liabilities | + | (Long-Term Debt & Capital Lease Obligation | + | Other Long-Term Liabilities | |
= | 0.538 | + | (0.306 | + | 0.00099999999999995 | |
+ | NonCurrent Deferred Liabilities | + | PensionAndRetirementBenefit) | |||
+ | 0 | + | 0) | |||
= | 0.85 |
Total Liabilities | = | Total Assets (Q: Dec. 2023 ) | - | Total Equity (Q: Dec. 2023 ) |
= | 9.285 | - | 8.441 | |
= | 0.84 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of CytoMed Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Chee Kong Choo | director, 10 percent owner | COMMONWEALTH LANE 08-22, SINGAPORE U0 149544 |
Jieming Zeng | director, officer: CSO and CMO | 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544 |
Shu Wang | 10 percent owner | 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544 |
Wee Kiat Tan | director, officer: Chief Operating Officer | 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544 |
Keng Kiat Toh | director | 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544 |
Glorious Finance Ltd | 10 percent owner | 18 NAMLY GROVE SOUTH, SINGAPORE U0 267310 |
Luk Lucas Tien Wee | director, officer: Chief Clinical Officer | 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544 |
Leong Mark Kei Wei | director | 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544 |
Chak Hua Yew | director | 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544 |
Yuin Han Loh | director | 1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544 |
From GuruFocus
By PRNewswire PRNewswire • 04-14-2023
By PRNewswire PRNewswire • 05-09-2023
By PRNewswire • 11-14-2023
By PRNewswire • 07-06-2023
By PRNewswire • 12-05-2023
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire • 11-17-2023
By PRNewswire • 08-01-2023
By PRNewswire • 09-25-2023
By ACCESSWIRE • 08-29-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.